Cereno Scientific’s innovative Phase II study design in PAH with CS1 is accepted for presentation at the CHEST annual meeting on Oct 16-19 in Nashville, US
Cereno Scientific (XSAT: CRNO B) today announced that an abstract on clinical Phase II drug candidate CS1 has been accepted at the CHEST annual meeting 2022 hosted by the American College of Chest Physicians (CHEST) in Nashville, US, on October 16-19. The abstract has been selected for an oral presentation and is titled “An innovative Phase 2 clinical trial design for the assessment of CS1 ‒ a novel therapy in the treatment of pulmonary arterial hypertension.” It will be presented by Dr. Raymond Benza, PI of Cereno’s Phase II study in PAH with CS1 and Professor and Director of the Division of